GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today shared positive in vitro findings showing that an investigational integrase strand transfer inhibitor (INSTI), VH4524184 (VH184), retained its antiviral activity and could be effective in countering second-generation INSTI resistance.

葛兰素史克股份有限公司（伦敦证交所/纽约证交所：葛兰素史克）宣布，由葛兰素史克控股的全球专业艾滋病毒公司ViiV Healthcare，辉瑞和Shionogi为股东，今天在体外试验中取得了积极的结果，表明一种研究性整合酶链转移抑制剂（INSTI），VH4524184（VH184），保留了其抗病毒活性，可能有效对抗第二代INSTI耐药性。

Additional analysis presented of a phase I study showed pharmacokinetic (PK) and safety data supported further development of VH184.1 The findings are being presented at the 25th International AIDS Conference (AIDS 2024) being held in Munich, Germany, from 22 – 26 July 2024..

对I期研究的进一步分析表明，药代动力学（PK）和安全性数据支持了VH184的进一步发展。研究结果将于2024年7月22日至26日在德国慕尼黑举行的第25届国际艾滋病会议（艾滋病2024）上公布。。

Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: “ViiV Healthcare’s ambition is to end the HIV epidemic, in large part, by delivering a new generation of long-acting medicines for people seeking options to treat or prevent HIV. VH184, the first third-generation integrase inhibitor, with the potential for long-acting dosing and coverage of INSTI resistant viruses, builds upon our legacy of developing novel agents that address unmet needs.”.

ViiV Healthcare研发负责人、医学博士金伯利·史密斯（Kimberly Smith）表示：“ViiV Healthcare的目标是在很大程度上通过为寻求治疗或预防艾滋病毒选择的人提供新一代长效药物来结束艾滋病毒的流行。VH184是第一种第三代整合酶抑制剂，具有长效给药和覆盖INSTI耐药病毒的潜力，它建立在我们开发解决未满足需求的新药的传统之上。”。

The presentation at AIDS 2024 is a combination of two separate analyses. The first evaluated VH184, in vitro, against more than 20 clinically derived HIV-1 viruses with mutations known to be associated with resistance to INSTIs. These viruses were identified from two phase III clinical trials of second-generation integrase inhibitors in treatment-experienced people living with HIV.

。第一个在体外评估了VH184，针对20多种临床衍生的HIV-1病毒，这些病毒的突变已知与对INSTI的抗性有关。这些病毒是从第二代整合酶抑制剂在有治疗经验的HIV感染者中进行的两项III期临床试验中鉴定出来的。

The second analysis comes from a double-blind, randomised, placebo-controlled phase I study that evaluated the PK and safety of an oral version of VH184 in 84 participants without HIV. The study showed VH184 achieved drug levels in the blood that could potentially exhibit sufficient antiviral activity against the clinically derived INSTI mutations seen in vitro.

第二项分析来自一项双盲，随机，安慰剂对照的I期研究，该研究评估了84名无HIV参与者口服VH184的PK和安全性。该研究表明，VH184在血液中达到了药物水平，可能对体外观察到的临床衍生的INSTI突变表现出足够的抗病毒活性。

Administration of VH184 was also well tolerated with no adverse events (AEs) leading to participant discontinuation. AEs were generally mild (n=44 in 29 participants), few were considered to be related to VH184 (n=6 in 5 participants, all of which were mild) and none were serious..

VH184的给药也具有良好的耐受性，没有导致参与者停药的不良事件（AE）。AE通常是轻度的（29名参与者中有44名），很少被认为与VH184有关（5名参与者中有6名，所有参与者都是轻度的），没有一个是严重的。。

ViiV Healthcare is also conducting a phase I study evaluating long-acting injectable formulations of VH184 in participants without HIV. Additionally, a phase IIa proof-of-concept study is underway to define the efficacy, safety, and tolerability of VH184 in people living with HIV who are naïve to antiretroviral therapy..

ViiV Healthcare还正在进行一项I期研究，评估无HIV参与者中VH184的长效注射制剂。此外，正在进行IIa期概念验证研究，以确定VH184在未接受抗逆转录病毒治疗的艾滋病毒感染者中的疗效，安全性和耐受性。。

About ViiV Healthcare

关于ViiV医疗

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012.

ViiV Healthcare是由葛兰素史克（LSE:GSK）和辉瑞（NYSE:PFE）于2009年11月成立的一家全球专业HIV公司，致力于为艾滋病毒感染者和有感染艾滋病毒风险的人提供治疗和护理方面的进步。Shionogi于2012年10月成为ViiV股东。

The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com. .

该公司的目标是比以往任何公司都对艾滋病毒和艾滋病产生更深入和更广泛的兴趣，并采取新的方法提供有效和创新的艾滋病毒治疗和预防药物，以及支持受艾滋病毒影响的社区。有关公司、管理层、投资组合、渠道和承诺的更多信息，请访问viivhealthcare.com。